6 Best Targeted Therapy Clinics in China

Xiamen Humanity Hospital is a private multi-specialty medical center located in Xiamen, China, specializing in neurosurgery, orthopedics, oncology, and ophthalmology. It is a tertiary, not-for-profit general hospital with over 47 clinical and technical departments, 1,000 inpatient beds, and a total area of 330,000 m². The hospital is accredited to conduct Phase I–IV drug trials, as well as clinical trials for medical devices and IVD products. Xiamen Humanity Hospital serves both adults and children, treating around 1,000,000 patients annually, with patients from CIS countries, Europe & Commonwealth, and Asia visiting most often.

Shanghai Tongji Hospital’s CAR-T program has performed 1,500+ infusions since 2014. The hospital reports an 87.5% complete remission rate at three months among lymphoma patients. Its treatment pathway includes eligibility testing, cell preparation, infusion, and long-term follow-up. A multidisciplinary tumor board supports planning, and the program also offers CAR-NK cell therapy and epigenetic immunotherapy for some refractory cases. The hospital is affiliated with Tongji University and publishes research on next-generation CAR-NK therapies.

Fuda Cancer Hospital specializes in advanced cancer treatments, including targeted therapy with personalized approaches for late-stage cases. Professor Niu Lizhi, a renowned oncologist with 10,000+ minimally invasive procedures, leads the team as hospital president. He is Vice-President of the International Society of Cryosurgery and author of 100+ oncology papers. Targeted therapy typically costs $10,500–$18,900. The JCI-accredited hospital has treated over 30,000 international patients with cutting-edge techniques.

Boao International Medical Center is a private multidisciplinary medical center located in Hainan, China. The clinic specializes in oncology, neurology, kidney diseases, diabetes, rehabilitation, stem cell therapy, and Traditional Chinese Medicine (TCM).

The center provides care for both adults and children, and more than 20,000 patients receive treatment there each year. It welcomes international patients, particularly from Europe, Commonwealth countries, Africa, and Asia, supported by a multilingual medical team.

Jinshazhou Hospital pioneered the first Y-90 microsphere precision treatment in South China. This tertiary hospital holds the highest Chinese classification and houses 31 laminar-flow operating rooms. The oncology center manages over 1,500 beds, providing a massive infrastructure for targeted radionuclide therapy. As a co-host of the CSCO-South Forum on Molecular Targeted Therapy, the institution leads national research in biotherapy. These specialists focus on Y-90 resin microspheres for internal radiotherapy, especially when treating complex liver tumors.